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![Schematic representation of the RAR proteins with the functional domains and the main phosphorylation sites.\
RARs have a modular structure composed of six conserved regions designated A to F. The C region contains the DBD. The E region contains several domains, the LBD, the AF-2 domain, the cyclin H binding domain and the dimerisation domain. It also contains a phosphorylation site for several kinases (PKA and MSK1). The N-terminal domain (NTD) corresponds to regions A and B and contains a proline-rich motif with phosphorylation sites for Cdks and MAPKs.](nrs07005.f2){#fig2}

![Crosstalk between kinase cascades and genomic pathways induced by RA.\
In response to RA, PKCδ, p38MAPK and the downstream protein kinase MSK1 are activated through rapid nongenomic effects that occur in the cytosol or at the membrane. MSK1 phosphorylates RARα at S369 located in the LBD, subsequently allowing the docking of cyclin H within TFIIH and the formation of a RARα/TFIIH complex. Then the cdk7 subunit of TFIIH phosphorylates the NTD of RARα at S77. Finally, RARα phosphorylated and associated with TFIIH is recruited to response elements located in the promoter of target genes. P38MAPK, MSK1 and PKCδ also phosphorylate corepressors, coactivators and histones. All these phosphorylation processes cooperate to coordinate and fine-tune the dynamic exchanges between RARs, coactivators, corepressors and the promoters of target genes](nrs07005.f3){#fig3}

![Recapitulation of the different signaling pathways involved in RAR phosphorylation.\
The pathways that are induced by RA are in red. The consequences (positive or negative) of RAR phosphorylation on RA target genes transcription are also indicated. (1) Gianni *et al.*, 2002a. (2) Bour *et al.*, 2005b. (3) Sun *et al.*, 2007. (4) Delmotte *et al.*, 1999. (5) Srinivas *et al.*, 2005. (6) Bruck *et al.*, 2009. (7) Rochette-Egly *et al.*, 1997. (8) Poon and Chen, 2008.](nrs07005.f4){#fig4}

Introduction
============

Nuclear retinoic acid (RA) receptors (RARs) consist of three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3) encoded by separate genes \[[@r3]; [@r1]\], which function as ligand-dependent transcriptional regulators heterodimerized with retinoid X receptors (RXRs). For each subtype, there are at least 2 isoforms, which are generated by differential promoter usage and alternative splicing and differ only in their N-terminal regions. Activation of RARs by cognate ligands triggers transcriptional events leading to the activation or repression of subsets of target genes involved in cellular differentiation, proliferation and apoptosis (\[[@r7]\], and references therein).

The compounds that bind RARs and modulate their activity are referred to as retinoids. This generic term covers molecules that include natural vitamin A (retinol) metabolites and active synthetic analogs. Retinoids are hydrophobic, lipid-soluble, and of small size, so that they can easily cross the lipid bi-layer of cell membranes.

Natural retinoids, exemplified by *all-trans* RA, are produced *in vivo* from the oxidation of vitamin A \[[@r8]; [@r9]\] ([Figure 1](#fig1){ref-type="fig"}). An isomerization product of RA, *9-cis* RA, also binds RARs with high affinity, but whether this compound is a natural bioactive retinoid remains controversial \[[@r2]\].

Beyond the natural compounds, major research efforts in retinoid chemistry have been directed towards the identification of potent synthetic molecules and led to the generation of several classes of compounds with a panel of activities ranging from agonists to antagonists, selective or not to RAR subtypes \[[@r10]\] ([Figure 1](#fig1){ref-type="fig"}).

Note that for (B) and (D) in [Figure 1](#fig1){ref-type="fig"}, a given ligand may be considered as selective for a certain RAR subtype when it exhibits an affinity difference greater than 100-fold between its primary target and other receptors (see the recommended usage of terms in the field of nuclear receptors \[[@r1]\]).

RARs have a well-defined domain organization and structure, consisting mainly of a central DNA-binding domain (DBD) linked to a C-terminal ligand-binding domain (LBD) ([Figure 2](#fig2){ref-type="fig"}). In the past 20 years, it has been established that the basic mechanism for transcriptional regulation by RARs relies on DNA binding to specific sequence elements located in the promoters of target genes and on ligand-induced conformational changes in the LBD that direct the dissociation/association of several coregulator complexes \[[@r11]; [@r12]; [@r13]; [@r14]\]. The description of the crystallographic structures of these domains and the characterization of the multiprotein complexes that specify the transcriptional activity of RARs provided a wealth of information on how these receptors regulate transcription. However, recent years have witnessed the importance of the ubiquitin-proteasome system and that of the N-terminal domain (NTD), which also interacts with specific coregulators, despite its native disordered structure \[[@r5]\]. Moreover, according to recent studies, RARs are involved in other nongenomic biological activities such as the activation of translation and of kinase cascades. These kinases target RARs and their coregulators, adding more complexity to the understanding of RAR-mediated transcription. In this review we will focus, in addition to the basic scenario (DNA and ligand binding, dynamics of coregulator exchanges at the LBD), on recent advances in the nongenomic effects of RA, and on how phosphorylation cascades, the NTD and the ubiquitin-proteasome system cooperate for fine-tuning RAR activity.

Structure/function analysis
===========================

As with most nuclear receptors, RARs exhibit a modular structure composed of 6 regions of homology (designated A to F, from the N-terminal to the C-terminal end) ([Figure 2](#fig2){ref-type="fig"}) harboring specific functions \[[@r11]; [@r13]\]. Regions C and E, which encompass the DBD and the LBD, respectively, are the most conserved and important domains and govern the classical model of RAR transcriptional activity. In contrast, the A/B, D, and F regions are poorly conserved.

The DNA binding domain (DBD)
----------------------------

The DBD, which confers sequence-specific DNA recognition, is composed of two zinc-nucleated modules, two α-helices and a COOH-terminal extension (CTE) \[[@r215]; [@r216]\]. Helix 1 and helix 2 cross at right angles to form the core of the DBD folding into a single globular domain that has been determined by nuclear magnetic resonance and crystallographic studies \[[@r15]\]. The DBD includes several highly-conserved sequence elements, referred to as P, D, T and A boxes, that have been shown to define or contribute to the response element's specificity, to a dimerization interface within the DBDs and to contacts with the DNA backbone and residues flanking the DNA core recognition sequence \[[@r12]; [@r1]\].

RARs bind as asymmetrically-oriented heterodimers with RXRs, to specific DNA sequences or RA response elements (RAREs), composed typically of two direct repeats of a core hexameric motif, PuG (G/T) TCA \[[@r12]; [@r201]; [@r203]\] and located in the regulatory sequences of target genes. The classical RARE is a 5bp-spaced direct repeat (referred to as DR5). However, the heterodimers also bind to direct repeats separated by 1bp (DR1) or 2bp (DR2). Note that RXR homodimers also bind to DR1.

RAREs have been identified in the promoters of a large number of RA target genes implicated in a wide variety of functions. For instance, the classical DR5 elements are found in the promoters of the *RARβ2* gene itself \[[@r20]\], of the *CYP26A1* (cytochrome 450, family 26, subfamily a, polypeptide 1) gene \[[@r21]\] and of several *Homeobox (Hox)* and *hepatocyte nuclear factor (HNF)* genes \[[@r23]; [@r22]\]. DR2 elements were identified in the *CRBPI (Cellular retinol binding protein I)* and *CRABPII (Cellular retinoic acid binding protein II)* gene promoters \[[@r24]; [@r213]\]. The only natural DR1 element has been found in the rat *CRBPII* gene promoter \[[@r26]\].

On DR2 and DR5 elements, *in vitro*, RXR occupies the 5' hexameric motif, whereas the RAR partner occupies the 3' motif (5'-RXR-RAR-3') \[[@r11]; [@r13]\]. In contrast, on DR1 elements, the polarity is reversed, with the RAR DBD binding upstream and the RXR DBD downstream (5'-RAR-RXR-3'), switching the activity of the heterodimer from an activator to a repressor of target genes in the presence of RA.

So far, it has proved difficult to visualize the full-length RXR-RAR heterodimer in complex with DNA. However, the crystal structure of the DBDs in complex with DNA has been solved \[[@r27]; [@r28]; [@r29]\]. Each DBD interacts with the DNA major groove at the level of a half-site through the P box of the first helix containing three exposed residues responsible for discrimination between different half-sites' sequences. Then, they arrange head-to-tail, with cooperative contacts between the DBDs, leading to a mutual reinforcement of protein-protein and protein-DNA interactions. Depending on the DR spacing, different regions of the DBD of each receptor are used to create the dimerization interface, in order to achieve the required binding to the response elements. The heterodimeric DBD interface that is responsible for the binding of RXR-RAR heterodimers to DR5 elements involves the D box of the RXR second zinc-finger, and the tip of the RAR first zinc finger. However, when the heterodimers bind with reverse polarity to DR1 elements, they associate through the second zinc finger of RAR and the so-called T box (within the CTE- of RXR). This implies that the DBDs must be rotationally flexible with respect to the LBD dimerization interface and that the DNA curvature is different (for review, see \[[@r30]\] and references therein). In conclusion, the DBDs of each heterodimerization partner dictate the specificity of RARE recognition and contribute through their dimerization to increase DNA binding efficiency.

The ligand binding domain (LBD)
-------------------------------

The structures of the RAR LBDs are rather similar, as demonstrated by crystallographic studies \[[@r204]; [@r30]; [@r32]\]. The LBD is formed by 12 conserved α helices and a β-turn (situated between H5 and H6). Helices 1-11 are folded into a three-layered, and parallel helical sandwich with H4, H5, H8, H9 and H11 sandwiched between H1, H2 and H3 on one side and H6, H7 and H10 on the other. In contrast, the C-terminal helix, H12, is more flexible and adopts conformations that may differ from one RAR subtype to the other (see below). The LBD is functionally complex, as it contains the ligand-binding pocket (LBP), the main dimerization domain and the ligand-dependent activation function-2 (AF-2).

**The ligand-binding pocket (LBP)**. The ligand-binding pocket (LBP) comprises hydrophobic residues mainly from helices H3, H5, H11 and the β-sheet, and crystallographic studies revealed the structural basis of ligand recognition \[[@r33]; [@r34]; [@r209]\]. The shape of the LBP matches the volume of the ligand, maximizing the hydrophobic contacts and contributing to the selectivity of ligand binding \[[@r36]; [@r37]; [@r199]\].

Given that the precise contacts with ligands involve three divergent residues located in H3, H5 and H11, which are unique for each subtype receptor-cognate ligand pair, it has been possible to generate subtype-selective ligands \[[@r40]\] ([Figure 1](#fig1){ref-type="fig"}). For instance, the unique polar residues S232 and M272 located in the LBP of RARα and RARγ, respectively, have been exploited to develop ligands that are specific for RARα (Am580) or RARγ (BMS270394 or CD666). Via their amino group, such ligands establish hydrogen bonds with RARα S232 or RARγ M272, thereby increasing affinity and selectivity for RARα and RARγ, respectively. However, as the RARβ LBP does not contain specific polar residues, the development of RARβ-selective ligands is more challenging \[[@r40]\]. Nevertheless, due to differences in the volume and the shape of the LBPs of each RAR subtype, it has been possible to generate molecules with complex activities such as ligands that are RARβ agonists and RARα/RARγ antagonists, the larger size of RARβ LBP accounting for this mixed profile \[[@r41]; [@r40]\].

**The heterodimerization surface**. The heterodimerization surface involves residues from helices H7, H9, H10 and H11, as well as loops L8-9 and L9-10 \[[@r42]; [@r44]\]. Helices H9 and H10 contribute to more than 75% of the total dimerization surface and constitute the core of the dimer interface. It has been proposed that in RXR-RAR heterodimers, ligand binding affects the stability and propagation of signals across the heterodimerization surface, indicating that the LBP and the dimerization interface are in some way energetically linked \[[@r43]\].

**The C-terminal helix 12, named AF-2**. The C-terminal helix 12, named AF-2, controls the ability of RARs to interact with coregulators. The analysis of the crystal structures of the unliganded and ligand-bound LBDs of RXRα and RARα, respectively \[[@r45]; [@r209]\], highlighted the crucial conformational flexibility of H12 and suggested a mechanism by which AF-2 becomes transcriptionally competent \[[@r48]; [@r47]\]. Upon ligand binding, a series of intra-molecular interactions cause the repositioning of H11 in the continuity of H10 and the concomitant swinging of H12 which moves in a mouse trap model, sealing the "lid" of the LBP and being tightly packed against H3 and H4. Consequently, ligand binding is stabilized, and a new hydrophobic cleft is formed between H3, H4 and H12 that generates a defined interaction surface for transcriptional coactivators. In contrast, in the case of the RARβ and RARγ subtypes \[[@r49]; [@r50]; [@r51]\], biochemical studies proposed that, even in the absence of ligand, H12 would interact with H3 and adopt a constitutively closed conformation that approximates the conformation of liganded RARα. The importance of H12 in regulating coactivator and corepressor binding is detailed below.

The N-terminal AF-1 domain (NTD)
--------------------------------

Early studies revealed the importance of the NTD of RARs, which corresponds to the A and B regions and includes the activation function AF-1, in the control of transcription of RA target genes \[[@r205]; [@r206]\]. However, they did not elucidate the underlying mechanism. It is interesting to note that within the NTD, the A region differs between the different subtypes and between isoforms \[[@r11]\]. In contrast, the B region is rather conserved and depicts a proline-rich motif, which contains phosphorylation sites ([Figure 2](#fig2){ref-type="fig"}). Most importantly, proline-rich motifs can bind proteins with SH3 (Src-homology-3) or WW (tryptophan-tryptophan) domains, with phosphorylation preventing or favoring the interaction \[[@r176]\].

In contrast to the DBD and the LBD, there are still no high-resolution structures available for the NTD of RARs. Several biochemical and structural studies coupled to structure prediction algorithms suggested that the NTDs of RARs, as well as any member of the nuclear receptor family, are of naturally-disordered structure \[[@r54]; [@r55]\]. Most importantly, it has recently emerged that unstructured proteins or domains may be functional, undergoing transitions to more ordered states or folding into stable secondary or tertiary structures upon binding to DNA response elements or to coregulatory proteins \[[@r56]; [@r57]\]. Moreover, disordered domains provide the flexibility that is needed for modification by enzymes such as kinases and ubiquitin-ligases \[[@r56]\]. Such modifications may induce changes in the structural properties of the domain with profound impacts on its interactions with coregulators and/or on the dynamics of adjacent structural domains.

The D region
------------

Poorly conserved, this region is considered to serve as a hinge between the DBD and the LBD, allowing rotation of the DBD. Therefore, it might allow the DBD and the LBD to adopt different conformations without creating steric hindrance problems. It also harbors nuclear localization signals.

The F region
------------

This region extends C-terminal to helix 12 in RARs, but is absent in RXRs. It is highly variable in length and sequence among the different RAR subtypes and its three-dimensional structure is still unknown. Interestingly, region F is phosphorylated at multiple positions that might modify the properties of RARs \[[@r58]; [@r211]\]. Though the functions of region F are still poorly understood, it has been suggested that, in the absence of ligand, this region would stabilize H12 of the RARα subtype in an unclosed conformation, thereby enhancing corepressor binding \[[@r50]\]. According to recent studies, this region would be also capable of binding to specific mRNA motifs \[[@r180]\].

The canonical RAR-mediated regulation of transcription with the LBD as the main actor
=====================================================================================

RARs are considered to be highly-regulated DNA-binding transcription factors that control transcription *via* several distinct mechanisms, including both repression and activation. Many years ago, it was established that after site-specific DNA binding, the final transcriptional activity of RARs depends on a set of associated proteins, the so-called corepressors and coactivators. From a molecular point of view, the discrimination between corepressors and coactivators is governed by the position of H12, which is directed by the ligand and contributes in a critical manner to the generation or removal of interaction surfaces.

The position of helix 12 governs the exposure of interaction surfaces for corepressors or coactivators
------------------------------------------------------------------------------------------------------

A recurring structural feature of corepressors and coactivators is the presence of highly-conserved motifs that are implicated in their recruitment at the LBD of RARs. The nuclear receptor corepressor (NCoR/NCoR1/RIP13) and silencing mediator for retinoid and thyroid hormone receptors (SMRT/NCoR2/TRAC) \[[@r74]; [@r196]; [@r63]\] contain in their C-terminal part two and three nuclear receptor interaction domains, respectively, with an LxxI/HIxxxI/L motif, which forms an extended α helix. Coactivators, which include essentially the p160 subfamily of steroid receptor coactivators (SRC), namely SRC-1 (also referred to as NCoA-1), SRC-2 (TIF-2, GRIP-1) and SRC-3 (pCIP, ACTR, AlB1, TRAM1, RAC3) \[[@r196]; [@r14]; [@r208]\], depict three copies of a highly-conserved LxxLL motif, which forms a short α helix.

In the absence of ligand, the surface of the RARα LBD presents a hydrophobic groove generated by H3, L3-4 and H4. It is worth noting that this surface is topologically related to that involved in coactivator interaction, but without H12 \[[@r62]\] it can bind the extended LxxI/HIxxxI/L motif of corepressors. The N-terminal part of this motif extends in such a way that it masks the H12 interaction interface, thus explaining why the binding of corepressors and coactivators is mutually exclusive. Interestingly, the RARγ and RARβ subtypes interact poorly with corepressors \[[@r49]; [@r51]; [@r63]\]. It has been proposed that hydrophobic interactions between H3 and H12 sequester H12 in a closed conformation, even in the absence of ligand, thus occluding the corepressor-docking site. Note that this closed conformation also prevents coactivator binding.

Upon ligand binding, RARα undergoes conformational changes and H12 becomes reoriented with a conserved glutamate residue forming a charge clamp with a lysine in H3. Such a charge clamp can specifically grip the ends of a helix of the specific length specified by the LxxLL motif of the coactivators, therefore allowing the leucine side chains to pack into the hydrophobic cavity. Because this ligand-activated charge clamp does not fit with the extended LxxI/HIxxxI/L motif of corepressors, it has been proposed that the alternative interactions of RARα with corepressors and coactivators originate from the difference in length of the interacting motifs that can be accommodated in the hydrophobic cleft in the two conformations \[[@r1]; [@r208]\].

Several crystal structures of RAR LBDs bound to synthetic retinoids revealed that ligand interactions with H11 and H12, or residues in their proximity, are primary determinants of helix 12 position, and that H12 can adopt not only the active and inactive positions, but also several intermediary positions. This implies that relatively subtle ligand modifications could significantly alter the conformation of the LBD and the H12 molecular switch, thereby generating distinct coregulator binding interfaces. Therefore, a panel of compounds comprising not only agonists, but also antagonists, inverse agonists and partial agonists, selective or not for RAR subtypes, have been generated \[[@r67]; [@r10]; [@r66]\] ([Figure 1](#fig1){ref-type="fig"}).

From a structural point of view, agonists induce the repositioning of helix 12 and contribute in a critical manner to the surface recognized by the LxxLL boxes of coactivators. In contrast, antagonists which present a bulky side-chain that cannot be accommodated within the agonist binding cavity, prevent RARs from adopting this conformation. Antagonists include pure AF-2 antagonists, exemplified by BMS195614, a selective RARα antagonist ([Figure 1](#fig1){ref-type="fig"}). The crystal structure of the BMS195614-bound RARα LBD complex revealed that H12 packs on the groove formed by the carboxy terminal part of H3, Loop L3-4 and H4 \[[@r33]\], which corresponds to the binding site for the coactivator LxxLL motif. Therefore, one can reason that BMS195614 may prevent interaction of coactivators. As the coactivator's binding site overlaps with that for corepressors, BMS195614 may also impede the interaction of NCoR and SMRT corepressors.

In contrast, other antagonists, referred to as inverse agonists and exemplified by AGN193109 or BMS204493 ([Figure 1](#fig1){ref-type="fig"}), are highly effective at inducing corepressor interaction and thereby enhance silencing \[[@r181]; [@r39]; [@r68]; [@r69]\]. Although the molecular basis of inverse agonism has not been elucidated yet, H12 of RAR LBD bound to an inverse agonist should adopt an alternative position, which does not occlude the hydrophobic groove formed by H3 and H4.

Finally, AF-2 partial agonists-antagonists have been identified \[[@r41]; [@r40]; [@r68]\]. The interest in such compounds, which exhibit reduced efficacy compared to full agonists, is that they can act in a cell type-selective manner and/or activate only a subset of the cognate ligand-induced functions.

Transcriptional repression in the absence of ligand
---------------------------------------------------

When genes are silent, DNA is packaged into a highly-organized and compact nucleoprotein structure known as heterochromatin, which limits the access of promoter sequences to the transcriptional machinery and therefore impedes all the transcriptional steps \[[@r70]\]. The basic unit of chromatin is the nucleosome, which consists of DNA wrapped around a protein core containing two copies each of four histone proteins. Protruding from the nucleosomes are the N-terminal "tails" of the core histones, whose interaction with DNA can be modulated upon covalent modifications (acetylation, phosphorylation, methylation, ubiquitination, etc.) \[[@r71]\].

According to the current model of gene regulation by RARs \[[@r72]\], in a context of chromatin where the nucleosomes do not impede binding to RAREs, the RARα subtype is a strong repressor of target gene expression in the absence of ligand. This repressive activity reflects the ability of RARα to bind corepressors such as NCoR or SMRT (see above), which do not harbor intrinsic enzymatic activities, but reside in or recruit high molecular weight complexes endowed with histone deacetylase activity (HDACs). Such complexes have a well-characterized role in transcriptional repression by deacetylating lysine residues in the N-terminal tails of histones and generating a condensed chromatin structure over the target promoter. The corepressor complexes also contain other components such as TBL1 (Transducin β-like 1) and TBLR1 (TBL1-related protein 1), which serve as adaptors regulating corepressor assembly and function \[[@r75]\].

It is worth noting that according to recent studies, in the absence of RA, RAR target genes have also been shown to interact with other kinds of repressors such as Topoisomerase IIβ \[[@r76]\], Polycomb group proteins (PcG) \[[@r77]; [@r78]\] or calmodulin kinase IIγ (CaMKIIγ) \[[@r79]\], which also dissociate in response to RA. PcG proteins act in large multimeric complexes that mediate gene silencing, while CaMKIIγ phosphorylates RARs, thereby enhancing their interaction with corepressors.

Transcriptional activation upon ligand binding: coregulator exchange at the LBD
-------------------------------------------------------------------------------

To activate gene expression, RXR-RARα heterodimers bound at DR5 elements will have to contend with the repressive chromatin structures in order to allow the recruitment of the transcriptional machinery. Today, it is widely accepted that upon binding of a RARα agonist, bound corepressors are released and RXR-RARα heterodimers interact with coactivators of the p160 family (see above) that upon association with larger complexes with chromatin modifying and remodeling activities will decompact repressive chromatin.

Interestingly, an RXR agonist cannot activate RXR-RARα heterodimers unless the RARα partner is liganded first. Several models have been proposed to account for this phenomenon referred to as "subordination" or "silencing" (for review see \[[@r197]\] and references therein), but most of them require more crystal structures for validation. Importantly, one model proposed that liganded RXR cannot dissociate corepressors from the RARα partner \[[@r39]\] and that the binding of agonists to RARα is essential for corepressor dissociation. In agreement with this idea, the RXR-RARβ heterodimer, in which RARβ only weakly recruits corepressors, responds better to a RXR agonist \[[@r39]\]. Finally, in the presence of both RAR and RXR agonists, there is synergy originating from the RAR agonist-induced dissociation of corepressors and the subsequent cooperative binding of coactivators to the two partners.

The p160 coactivators serve as adaptors recruiting other complexes with different enzymatic activities \[[@r196]; [@r14]; [@r81]; [@r82]; [@r83]\]: (i) histone acetyltransferases (HATs) such as CBP/p300 (CREB binding protein) and p/CAF (p300/CBP-associated factor) (ii) histone methyl transferases (HMTs) such as CARM1 (coactivator-associated arginine methyltransferase 1) or PRMT1 (protein arginine methyl transferase 1), (iii) ubiquitinases/deubiquitinases and (iv) nucleosome remodeling complexes such as SWI/SNF (switch/sucrose non-fermenting). All these complexes alter the chromatin structure surrounding the promoter of target genes and create tags or binding sites that form a "histone code" read by particular effectors, which in turn mediate distinct outcomes \[[@r84]\]. In some examples, these chromatin marks function in a combinatorial manner. This code coordinates the recruitment of additional HATs or HMTs for further chromatin decompaction. It also orchestrates the recruitment of chromatin remodelers, which use the energy of ATP-hydrolysis to reposition nucleosomes through sliding them in *cis* or displacing them in *trans*, allowing the formation of nucleosome-free or nucleosome-spaced regions at the promoter \[[@r71]\]. It has also been proposed that activated RARs recruit the transcriptional machinery, including the multisubunit Mediator complex, RNA polymerase II and the general transcription factors \[[@r85]; [@r72]; [@r59]; [@r82]\]. This step would require the association of RARs with a specific subunit of the Mediator complex, which was identified as DRIP205/TRAP220, and which contains two LxxLL motifs \[[@r14]\].

It must be noted that, *in vivo*, RARs appear to employ different programs for gene activation, depending on the target gene promoter context. Indeed, recent chromatin immunoprecipitation experiments demonstrated that *in vivo*, the Mediator complex and RNA PolII can already occupy with RARα the promoters of some endogenous genes, even in the absence of RA \[[@r87]; [@r86]; [@r75]\]. In that context, transcription initiation and the recruitment of the general transcription factors such as TFIIH at the promoter have been shown to depend on the dissociation from the Mediator complex, of the inhibitory cyclin-dependent kinase 8 (cdk8) subunit \[[@r89]; [@r88]\]. In addition, recent studies from our laboratory revealed that in the absence of ligand, not all RA target promoters are occupied by RARs and that several events have to be initiated and coordinated to make the response elements available for RAR recruitment (see below and \[[@r90]\]). Interestingly, in the context of promoters with RAREs that are distant from the transcription start site, RARs in association with coregulators and RNA PolII initiate the formation of DNA loops \[[@r90]\].

Role of other unconventional coregulators
-----------------------------------------

The model involving coactivators that positively modulate transcription has been challenged by the identification of three other unconventional coregulators, the receptor interacting protein of 140kDa (RIP140/NRIP1) \[[@r91]; [@r194]\], the preferentially expressed antigen in melanoma (PRAME) \[[@r92]\] and the transcription intermediary factor-1 α (TIF1α/Trim24) \[[@r200]\], which repress transcription despite their ligand-dependent recruitment to RARs via LxxLL motifs (one in TIF1α, seven in PRAME and nine plus a modified LxxML motif in RIP140) \[[@r95]; [@r94]\]. In fact, these coregulators would constitute a functional negative feedback mechanism limiting and/or ending RAR activity. The mechanism of TIF1α-mediated repression has not been elucidated yet \[[@r96]\]. However, the repressive activity of RIP140 has been attributed to the presence of four autonomous repressive domains, one of them recruiting HDACs \[[@r97]\], and that of PRAME to the recruitment of PcG proteins \[[@r92]\].

A plethora of other coregulator molecules for RA-bound RARs has been identified. Among these, are coactivators devoid of LxxLL motifs such as the thyroid receptor interacting protein-1 (TRIP1/SUG-1) \[[@r214]\], which is a subunit of the 19S regulatory subcomplex of the proteasome with an ATPase activity and which contributes to the transcription of RAR target genes \[[@r99]\]. There are also coregulators that interact with domains other than the coactivators hydrophobic cleft formed between H3, H4 and H12. As such, cyclin H interacts with L8-9 and the beginning of H9 \[[@r4]\], allowing the recruitment of TFIIH (see below). There is also CRABPII, which in association with cyclin D3 \[[@r100]; [@r101]\], serves as a RA-channeling molecule to the receptor \[[@r103]; [@r102]\]. Interestingly, upon deregulation of CRABPII expression, RA is shuttled to peroxisome proliferator-activated receptors (PPARβ/δ) rather than to RARs, by another intracellular lipid-binding protein, generating RA resistance \[[@r104]\].

New unconventional nongenomic effects of RARs: kinase activation and translation induction
==========================================================================================

Activation of the MAPK pathways
-------------------------------

A new concept, which has recently developed is that, in addition to its well-established nuclear function to regulate gene expression, RA rapidly activates mitogen-activated protein kinases (MAPKs). Indeed, recent studies indicated that RA activates p38MAPK in several cell lines such as fibroblasts, mouse embryocarcinoma cells, mammary breast tumor cells and leukemia cells \[[@r107]; [@r90]; [@r195]; [@r110]\]. Subsequently, p38MAPK activates a downstream mitogen and stress-activated kinase, MSK1 \[[@r90]\]. However, in neuronal cells (neuroblastoma cells, hippocampus neurons and P19 cells) and Sertoli cells, RA instead rapidly activates p42/44 MAPKs \[[@r112]; [@r198]; [@r105]; [@r179]\].

MAPK activation occurs very rapidly (within minutes after RA addition) subsequent to the prior activation of upstream kinases such as phosphoinositide 3-kinase (PI3K) \[[@r183]; [@r105]; [@r184]\], RAC-1 \[[@r107]\] or protein kinase C δ (PKCδ) \[[@r187]; [@r185]\]. This suggests an atypical, nongenomic activation event similar to that described for steroid receptors. In line with this new concept, though classically thought to reside in the nucleus, RARs have been recently reported to be present in the cytosol or in membranes, in association with PI3K or Src kinases \[[@r106]; [@r105]\]. Such observations strongly suggest a new paradigm by which RARs would integrate membrane/cytoplasm events that would orchestrate several post- t reductional modifications in order to fine-tune transcription ([Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}).

RNA binding and translation control
-----------------------------------

Very recent studies suggested another new nongenomic role of RARα as a RNA-binding protein. Two laboratories independently demonstrated that RA activates dendrite protein synthesis via a process that requires RARα (and not the other RAR subtypes) and is independent of transcriptional regulation \[[@r112]; [@r172]\]. Indeed, they found that RARα is exported to neuronal dendrites, where it is associated with a subset of mRNAs such as the glutamate receptor 1 (GluR1) mRNA \[[@r113]\]. This binding, which is mediated by the C-terminal F region of RARα, directly represses the translation of these mRNA \[[@r180]\]. Interestingly, RA binding to RARα reduces its association with GluR1 mRNA and relieves translational repression. Such effects have been correlated to synaptic function and plasticity \[[@r171]\]. As RA also activates MAPKs in neuronal cells \[[@r112]\] and as the F region can be phosphorylated \[[@r211]\], further studies are required to delineate the influence of the kinase signaling pathways on translation \[[@r112]\]. Overall, these new nongenomic effects expand the scope of the biologic functions of RARα beyond its role as a regulator of gene transcription.

Crosstalk between kinase cascades and genomic pathways induced by RARs
======================================================================

The RA-activated p38MAPK/MSK1 pathway leads to a coordinated phosphorylation cascade targeting RARα, their coregulators and histones
------------------------------------------------------------------------------------------------------------------------------------

Recent studies from our laboratory demonstrated that RARα becomes rapidly phosphorylated in response to RA at two serine residues, one being located in the LBD (serine 369) and the other one in the NTD (serine 77) \[[@r90]\] ([Figure 2](#fig2){ref-type="fig"}). Interestingly, serine 369 is an exposed residue located between helices 9 and 10 within the LBD. It belongs to an arginine-lysine-rich motif that corresponds to a consensus phosphorylation motif for several kinases including the cyclic AMP-dependent protein kinase (PKA) and MSK1, suggesting that it might integrate several signaling pathways \[[@r90]; [@r114]\]. In contrast, serine 77 located in the NTD, belongs to a proline-rich motif. The kinase responsible for phosphorylating this site has been identified as cdk7 \[[@r211]\], the activity of which depends on its association with cyclin H and MAT1 to form the ternary cyclin-dependent kinase (CDK)-activating kinase (CAK) complex of TFIIH, a general transcription factor composed of 10 subunits \[[@r115]\]. The correct positioning of the cdk7 kinase and thereby the efficiency of the NTD phosphorylation by cdk7 rely on the docking of cyclin H at a specific site of the LBD located in L8-9 and the N-terminal part of H9 \[[@r4]; [@r114]\]. To our knowledge, it was the first example of cooperation between the N- and C-terminal domains of RARs through a kinase complex. The docking site of cyclin H is conserved between RARs, but not in other nuclear receptors and other cdk7 targets, and differs from the other cyclin docking sites. Therefore, it would elicit the specificity of RAR phosphorylation by cdk7.

Recently, Bruck *et al.* demonstrated that the RA-induced phosphorylation of RARα results from a coordinated phosphorylation cascade starting with the phosphorylation of serine 369 by MSK1 \[[@r90]\]. As serine 369 is in close proximity to the docking site for cyclin H, phosphorylation of this residue induces an allosteric network, which promotes the binding of cyclin H \[[@r114]\] and thereby of cdk7, with a characteristic downstream consequence on the phosphorylation of the NTD at serine 77.

The phosphorylated serine residues located in the LBD and in the NTD are conserved between RARs. Accordingly, the RARγ subtype is also phosphorylated at the NTD (serine 79 in RARγ1 and serine 68 in RARγ2) by the cdk7 subunit of TFIIH \[[@r85]\]. Interestingly, RARγ (but not RARα) is also phosphorylated at an additional nearby serine residue (serine 77 in RARγ1 and serine 66 in RARγ2) by p38MAPK \[[@r195]; [@r109]\] ([Figure 2](#fig2){ref-type="fig"}). However, whether RARγ can be phosphorylated at the LBD site (serine 371 in RARγ1 and serine 360 in RARγ2) \[[@r212]\] by MSK1 in response to RA remains to be demonstrated.

RA also activates p42/p44MAPK, but whether this kinase is able to phosphorylate RARs has not been elucidated yet. Note, however, that in neuronal cells, RA-activated p42/p44MAPK phosphorylates other activators of transcription, switching them into repressors of other gene programs \[[@r198]\], while in Sertoli cells, they induce apoptosis \[[@r179]\].

Recently, the p160 SRC-3 coactivator \[[@r110]\] and TBLR1, a component of the corepressor complexes \[[@r64]\], have also been shown to be phosphorylated in response to RA by p38MAPK and PKCδ, respectively. Interestingly, the p160 family of coactivators \[[@r121]; [@r120]; [@r190]; [@r188]; [@r189]\], as well as p300/CBP \[[@r122]\], RIP140 \[[@r123]; [@r124]\] and SMRT \[[@r125]\], are also targets for MAPKs or other kinases, but whether their phosphorylation occurs in response to RA will require further investigations. Finally, MSK1 was recently found to be recruited to RARα target promoters in the active phosphorylated form, leading to increased phosphorylation of serine 10 on histone H3 \[[@r90]\].

RAR phosphorylation and the transcription of RA target genes
------------------------------------------------------------

Early studies demonstrated the importance of TFIIH-mediated phosphorylation of RARs in the transcription of RA target genes \[[@r58]; [@r211]\]. This has been corroborated in studies using cells from patients suffering from Xeroderma pigmentosum, which harbor mutations in a TFIIH subunit \[[@r116]\]. Such cells are characterized by a hypophosphorylation of the RARα subtype and a deficient RA response, but the underlying mechanism was not elucidated.

The recent results by Bruck *et al.* \[[@r90]\] provided new information on how phosphorylation influences the transcriptional activity of RARα. Indeed, they demonstrated that the RA-induced phosphorylation cascade initiated by MSK1 and ending with the phosphorylation of the NTD by cdk7, promotes RARα recruitment to target promoters. Such results corroborate the importance of NTD phosphorylation in the transcriptional activity of RARs. However, it raises the question as to how phosphorylation of this unstructured domain can actually regulate DNA binding. In contrast, in the case of RARγ, the promoters are already occupied by the receptor in the absence of ligand \[[@r77]; [@r78]\] and RARγ phosphorylation occurs at the promoters (our unpublished results), suggesting that phosphorylation of the NTD might modulate transcription through controlling protein-protein interactions \[[@r54]; [@r55]\].

Phosphorylation of coactivators and corepressors that occurs in response to RA is also crucial for RARα transcriptional activity \[[@r75]; [@r82]\]. Analogous to steroid nuclear receptors \[[@r117]; [@r118]; [@r119]\], it has been suggested that SRC-3 phosphorylation \[[@r110]\] fine-tunes the dynamics of the exchanges of the coactivator with RARα and/or other coregulators. In contrast, phosphorylation of TBLR1 mediates ubiquitination and degradation of NCoR/SMRT \[[@r64]\] and thereby overcomes SMRT/NCoR-dependent repression.

Finally, MSK1-mediated phosphorylation of H3 contributes to RARα target gene induction, probably as a chromatin mark accounting, in cooperation with other histone modifications, for the dissociation of repressive complexes and/or the recruitment of chromatin-remodeling complexes \[[@r90]; [@r192]\].

In conclusion, these recent findings challenged the conventional view of stable RAR-based, template-bound complexes and suggested a dynamic model with rapid, and sequential series of exchanges between RARs and coregulators at the promoter \[[@r5]; [@r59]\] ([Figure 3](#fig3){ref-type="fig"}). Such exchanges, carefully coordinated by phosphorylations, would act as a "transcriptional time clock", so that at the end, the correct proteins are present with the right activity, at the right place and at the right time.

RAR phosphorylation and other posttranslational modifications
-------------------------------------------------------------

According to recent studies, RARs are also targets for other modifications such as ubiquitination and methylation. Today, it is accepted that interplay between different posttranslational modifications is an important mechanism to achieve an integrated regulation of RAR activity, suggesting that a protein code similar to that proposed for histones could be applied to RARs \[[@r84]\]. The best example of crosstalk between modifications is the phosphorylation-dependent ubiquitination and subsequent proteasomal degradation of the RARγ subtype \[[@r195]; [@r146]\]. Central to this phosphorylation function, was the observation that RARγ with the serines located in the NTD substituted with alanine residues exhibit reduced ubiquitination and degradation by the 26S proteasome upon cognate ligand binding. Whether phosphorylation controls the recruitment of the ubiquitin-proteasome machinery directly or indirectly through conformational changes would require further investigations.

RARs can also be methylated. Accordingly, the group of Li-Na Wei reported that RARα can be tri-methylated at a lysine residue located in the LBD \[[@r155]\] and mono-methylated at another lysine located in the DBD \[[@r154]\]. In both cases, methylation plays a positive role in RARα transcriptional activity, but the basal molecular mechanisms, as well as the methylases involved, remain to be characterized. Whether methylation functions in a combinatorial manner with phosphorylation also remains to be demonstrated. Finally, whether RARs, as most nuclear receptors, can also be targeted by other modifications such as acetylation or SUMOylation would require further investigations.

RAR phosphorylation in response to other cellular signaling pathways: abrogation of the RA response
---------------------------------------------------------------------------------------------------

Today, new roles for phosphorylation in regulation of RAR-mediated transcription are being discovered at an accelerated pace and it is increasingly clear that RAR phosphorylation can also occur in the absence of ligand. Indeed, several exogenous signals such as growth factors, insulin, stress or cytokines activate cytosolic kinase cascade pathways, ending at Akt, PKC or c-Jun N-terminal kinases (JNKs), which can enter the nucleus and phosphorylate RARs at residues different from those that are normally phosphorylated in response to RA ([Figure 4](#fig4){ref-type="fig"}). While such phosphorylation processes usually activate the transcriptional activity of steroid receptors \[[@r127]; [@r126]\], they instead inactivate RARα activity. As an example, PKC can phosphorylate the DBD of RARs, resulting in nuclear export \[[@r186]\] or in abrogation of RARs heterodimerization and binding to DNA \[[@r193]\]. Moreover, in cancers characterized by amplified or deregulated JNK or Akt activities, due to amplification of aberrant activity of receptor or cytoplasm tyrosine kinases \[[@r132]\], several residues located at the C-terminal end of RARα are phosphorylated, contributing to RARα degradation \[[@r130]; [@r131]\]. SMRT is also phosphorylated by Akt \[[@r133]\], with a subsequent stabilization of the RAR-SMRT interaction. The nongenomic effects of RARs on the p38MAPK/MSK1 pathway are also abrogated \[[@r90]\]. Finally, such cancers are RA-resistant \[[@r128]; [@r129]\].

In conclusion, RAR transcriptional activity, which is controlled by multiple players acting in a fine-tuned, spatially- and temporally-coordinated manner, requires the integrity of the signaling pathways.

New actors in RAR-mediated transcription: the ubiquitin-proteasome system and coregulators of the NTD
=====================================================================================================

New roles for the ubiquitin-proteasome pathway, with and without proteolysis
----------------------------------------------------------------------------

A new aspect is that, in response to RA, RARs \[[@r195]; [@r146]; [@r217]\], as well as their coactivators such as SRC-3 \[[@r110]\], are ubiquitinated and degraded by the 26S, which consists of the 20S proteolytic core capped by the 19S regulatory complex that recognizes the ubiquitinated proteins and prepares them for entry into the 20S core (reviewed in \[[@r147]\]). The degradation of RARs depends on the RA-induced recruitment at the AF-2 domain of the ubiquitin and/or degradation machineries \[[@r146]\]. In the particular case of the RARγ subtype, degradation and ubiquitination of the receptor depends on the prior phosphorylation of the NTD \[[@r195]; [@r146]\]. Degradation of SRC-3 also depends on the phosphorylation of the coactivator by p38MAPK \[[@r110]\].

The exact role of the proteolytic activity of the proteasome in RAR-mediated transcription is not yet clear \[[@r85]; [@r5]\]. Since RAR and SRC-3 degradation occurs rather late after RA addition, when transcription has declined, a radical hypothesis would be that as for most "activators" of transcription, proteasomal degradation provides an efficient way to limit RAR function and/or to signal the end of the transcriptional process \[[@r148]\]. However, according to the newly-arising concept that dynamic exchanges of coregulators are required for transcription to proceed, proteolysis might serve to clear out corepressors and/or coactivators so that other coregulators can subsequently bind \[[@r149]; [@r117]; [@r150]\]. In line with this theme, two components of the RAR coregulatory complexes, TBL1 and TBLR1, have been shown to serve as specific adaptors for the recruitment of the proteasome and the degradation of corepressors, in order to mediate their exchange for coactivators \[[@r75]; [@r64]\].

However, there is an increasing body of evidence that the ubiquitin-proteasome system would also play a role in the control of RA-mediated transcription without proteolysis. In that context, it is worth noting that SUG-1, one of the six ATPases of the 19S, interacts with RARs \[[@r214]\] and SRC-3 \[[@r99]\], and as such, is recruited to the promoters of RA target genes, thereby contributing to their transcription \[[@r99]\]. It has been proposed that the ATPase subunits of the 19S regulatory subcomplex would unfold or refold the components of the regulatory transcriptional complexes, such as the SAGA (spt-Ada-Gcn5-acetyl-transferase) complex \[[@r151]\], in order to facilitate their loading and/or removal at promoters. They would also reconfigure local chromatin in order to promote recruitment of appropriate histone modifiers \[[@r152]\]. Thus, the proteasome pathway would control the composition of complexes at the promoters of RAR target genes and the coordination of the different steps at the promoter, consistent with the idea that transcription is a dynamic process with continual exchange and turnover of coregulators \[[@r149]; [@r153]; [@r59]\].

A new role for the NTD of RARs via the binding of proteins with WW or SH3 domains
---------------------------------------------------------------------------------

The NTD phosphorylation site belongs to a proline-rich motif ([Figure 2](#fig2){ref-type="fig"}). Most importantly, such motifs bind proteins with SH3 or WW domains, with phosphorylation preventing or favoring the interaction \[[@r137]; [@r135]; [@r134]; [@r136]\]. In line with this, the phosphorylated NTD of RARα has been shown to bind the proline isomerase Pin1 (protein interacting with NIMA (never in mitosis A)) \[[@r138]; [@r182]\], a WW domain-containing protein which induces *cis-trans* isomerisation of the proline residues that follow the phosphorylated serines in order to create new specific recognition sites for interacting factors \[[@r178]\].

A recent study performed in our laboratory has uncovered an interaction between the unphosphorylated NTD of the RARγ subtype and vinexin β \[[@r6]\], which is one of a growing number of actin-binding proteins that are also present in the nucleus and modulate transcription \[[@r5]\]. Vinexin β is devoid of any enzymatic activity and is an adaptor characterized by the presence of three SH3 domains \[[@r140]\], with the third one, proximal to the C-terminus, being involved in the interaction with the proline-rich motif of RARγ. As vinexin β is a repressor of RARγ-mediated transcription, it has been proposed that it would act as a scaffold between RARγ and nuclear proteins that interact with its two other SH3 domains \[[@r141]; [@r142]\], potentially forming a trimeric complex that maintains RARγ in an inactive state \[[@r5]\]. In support of this hypothesis, is the recent description of a direct interaction between vinexin β and SAFB2 (scaffold attachment factor B2 protein), a novel nuclear receptor corepressor \[[@r143]\]. Importantly, the interaction with vinexin β occurs only when the cdk7 phosphorylation site within the proline-rich motif, is not phosphorylated \[[@r6]\] and vinexin β is released in response to RA (Lalevée and Rochette-Egly, unpublished results). The relative contribution of the ligand and of the cdk7-mediated phosphorylation of the NTD, in vinexin β dissociation, is a current matter of investigation in our laboratory.

Recently, other coregulators such as Acinus-S', a nuclear protein implicated in apoptotic chromatin condensation and mRNA processing, have been shown to interact with the C-terminal part of the NTD, thereby repressing RAR transcriptional activity \[[@r144]\]. However, this interaction involves residues distinct from those of the proline-rich motif, suggesting another mechanism of action.

Transrepression by RARs (anti-AP1)
==================================

Evidence has accumulated over the past few years that the action of RARs is not restricted to the regulation (positive or negative) of cognate target gene expression, but also concerns several other gene programs by interfering with other nuclear receptors \[[@r198]\] or with transcription factor complexes such as activating protein-1 (AP-1) (for review see \[[@r12]; [@r14]\]). The AP-1 complex regulates the expression of several genes involved in oncogenic transformation and cell proliferation. Its activity is determined by the composition of the dimers, which include members of the fos (c-fos, FosB, Fra-1 and Fra-2) and jun (c-jun, junB and junD) families, and which is controlled by a complex network of phosphorylations. The inhibition of AP-1-driven transactivation by RARs is the prototype of transrepression and has been revealed in the context of several genes such as the *collagenase* and *stromelysin* genes \[[@r157]; [@r156]; [@r207]\]. Generally, AP-1 inhibition is driven by liganded RARs, though AP-1 has been found to be inhibited in a ligand-independent manner by the RARβ subtype \[[@r159]; [@r160]\]. How RARs interfere with AP-1 activity and through which domains, is complex, and several models have been proposed (\[[@r161]; [@r14]\] and references therein), such as (i) a direct interaction with Jun/Fos family members, (ii) disruption of Jun-Fos dimerization (iii) competition with the recruitment of a common transcriptional coactivator such as CBP, or (iv) inhibition of JNKs, thereby preventing the phosphorylation-dependent activation of c-jun \[[@r162]\]. Despite these models, the molecular basis of the anti-AP-1 activity of RARs has remained elusive and debated \[[@r163]; [@r164]\].

In general, AP-1 inhibition correlates with the growth inhibitory effect of retinoids on tumors \[[@r165]\]. Therefore, the capacity of RARs to inhibit AP-1-responsive genes seems to be the basis for the chemo preventive and chemotherapeutic effects of RA in the treatment of hyperproliferative diseases \[[@r161]; [@r167]; [@r202]\]. In this context, selective retinoids that dissociate the inhibition of AP-1 activity from the classical RARE-dependent activation of transcription have been generated \[[@r41]; [@r168]; [@r210]\]. Such compounds are promising therapeutic agents and provide valuable tools to address the mechanism of the RAR/AP-1 crosstalk, the importance of which for growth control and cancer is now established.

Conclusion
==========

The well-established function of RARs is to regulate gene expression in the nucleus. In this context, it is clear that switching on RAR transcriptional activity relies on conformational changes induced by ligand binding and on dynamic series of exchanges with coregulatory complexes. However, today there is mounting evidence that RARs have a wider spectrum of biological activities, through nonconventional, nongenomic mechanisms. Indeed, in response to RA, RARs can activate translation, as well as signaling pathways, independently of transcriptional mechanisms. Further work is needed to determine how RARs activate MAPKs and how RAR phosphorylation at the NTD controls the association/dissociation of specific partners with SH3 or WW domains to modulate the transcription of RA target genes. Up to now, only a few proteins have been shown to interact with the NTD of RARs \[[@r6]; [@r138]; [@r144]\] and further studies are required to investigate whether the NTDs of the different RAR subtypes can interact with other proteins involved in processes such as mRNA processing and splicing, or are endowed with chaperone or actin-binding activities. As phosphorylation of the RARγ NTD marks the receptor for ubiquitination and proteasomal degradation, ubiquitin ligases might also be interesting candidates. Ultimately, the challenge is to decipher at the molecular level how coregulator exchanges at the NTD cooperate with phosphorylations to modulate transcription.

Finally, given that aberrant retinoid signaling mechanisms have been associated with several diseases \[[@r116]\] or cancers \[[@r128]; [@r129]\], more work is required to understand the molecular pathways that are controlled by RARs, notably those underlying the antiproliferative and anticancer activities of retinoids, with a particular effort on the role of phosphorylation processes. Moreover, in line with the improved use of retinoids in therapy, novel synthetic RAR ligands harboring increased selective properties with little toxicity compared with classical retinoids, will have to be generated. Finally, combination of retinoids with agents targeting kinases \[[@r173]\] or epigenetic modifications such as HDAC inhibitors \[[@r191]; [@r174]; [@r175]\] are increasingly being sought in order to improve the retinoid response and/or to overcome retinoid resistance.
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